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Abstract
The treatment response to anti-angiogenic agents varies among cancer patients and predic-
tive biomarkers are needed to identify patients with resistant cancer or guide the choice of
anti-angiogenic treatment. We present “the Cancer Angiogenesis Co-Culture (CACC)
assay”, an in vitro Functional Precision Medicine assay which enables the study of tumour-
oid induced angiogenesis. This assay can quantify the ability of a patient-derived tumouroid
to induce vascularization by measuring the induction of tube formation in a co-culture of vas-
cular cells and tumoroids established from the primary colorectal tumour or a metastasis.
Furthermore, the assay can quantify the sensitivity of patient-derived tumoroids to anti-
angiogenic therapies. We observed that tube formation increased in a dose-dependent
manner upon treatment with the pro-angiogenic factor vascular endothelial growth factor A
(VEGF-A). When investigating the angiogenic potential of tumoroids from 12 patients we
found that 9 tumoroid cultures induced a significant increase in tube formation compared to
controls without tumoroids. In these 9 angiogenic tumoroid cultures the tube formation could
be abolished by treatment with one or more of the investigated anti-angiogenic agents. The
3 non-angiogenic tumoroid cultures secreted VEGF-A but we observed no correlation
between the amount of tube formation and tumoroid-secreted VEGF-A. Our data suggests
that the CACC assay recapitulates the complexity of tumour angiogenesis, and when clini-
cally verified, could prove a valuable tool to quantify sensitivity towards different anti-angio-
genic agents.
Introduction
Impaired control of angiogenesis is involved in numerous pathological conditions and is a
hallmark of cancer progression and metastasis [1–3]. Solid tumours are constantly influenced
by the distance to nearest capillary and growth beyond a diameter of 2 mm requires
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vascularization of the tumour to facilitate continuous diffusion of oxygen and nutrients [4].
This neovascularization occurs by several mechanisms including sprouting angiogenesis and
vascular co-option, where cancer cells grow along existing vessels in the peri-tumoural tissue
and integrate them in the expanding tumour [5]. Histological analyses of premalignant, non-
invasive lesions, showed that angiogenesis is an early event during the development of invasive
cancers [6]. Formation of new vessels includes endothelial cell proliferation and migration fol-
lowed by assembly into a new vascular structure, lumen formation and, finally, maturation of
the newly formed endothelial tube [5]. Neovascularization is initiated by changes in the bal-
ance between pro- and anti-angiogenic molecules in the microenvironment of the tumour [6].
The most potent pro-angiogenic factor under both physiological and pathological conditions
is vascular endothelial growth factor (VEGF)-A [7].
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide [8]. At
time of diagnosis, approximately 20% of colorectal cancer patients have synchronous metasta-
ses. In total, close to 50% develop metastases at some point during the clinical course of their
disease [9]. Treatment of metastatic colorectal cancer (mCRC) often includes chemotherapeu-
tics and a molecular targeted agent, such as an anti-angiogenic agent [10]. Anti-angiogenic
therapy can normalize the tumour vasculature by interfering with angiogenic ligands, their
receptors or their downstream signalling [11]. Normalization is obtained when the equilib-
rium between pro- and anti-angiogenic factors is restored, typically within 1–2 days after treat-
ment initiation. Effective anti-angiogenic treatment enhances the vascular circulation and
decreases the interstitial pressure of the tumour which improves the delivery of both nutrients
and chemotherapeutics [12].
The first anti-angiogenic agent to be approved by the FDA in malignancies was the ligand
trapping humanized monoclonal antibody bevacizumab [13, 14]. Bevacizumab binds to and
neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments [15, 16]. A pooled
analysis from seven randomized controlled trials in mCRC showed that addition of bevacizu-
mab to a chemotherapeutic backbone increased median overall survival (OS) from 16.1 to 18.7
months (p = 0.0003) and progression free survival from 6.4 to 8.8 months (p<0.0001) [17].
Several anti-angiogenic agents have subsequently been approved for the treatment of various
malignancies, including the first-generation tyrosine kinase inhibitors (TKIs) sorafenib and
sunitinib and the second generation TKI regorafenib. Sorafenib was FDA approved for the
treatment of advanced renal cell carcinoma in 2005 and sunitinib received FDA approval for
the treatment of gastrointestinal stromal tumours and advanced renal cell carcinoma in 2006
[18, 19]. Regorafenib was approved as monotherapy in third-line treatment of mCRC after
studies showed a significant increase in OS from 5.9 months in the placebo group to 6.4
months in the regorafenib group (p = 0.0052) [20, 21]. The TKIs are pan-kinase inhibitors, but
all of them target VEGFR-2, platelet-derived growth factor receptor β (PDGFRβ) and in the
case of regorafenib and sorafenib fibroblast growth factor receptor (FGFR) [22–24].
Numerous studies have focused on Precision Medicine in order to optimize treatment,
improve outcome and avoid undesired adverse effects of ineffective treatments for each patient
[25–31]. Suggested predictive biomarkers for anti-angiogenic treatment include intratumoural
and plasma VEGF-A levels, tumour imaging, histopathological growth patterns, pro-inflam-
matory cytokines, soluble VEGF receptors, gene signatures, and polymorphisms in the
VEGF-A pathway genes. Most of these biomarkers were suggested on the basis of results from
small patient series or retrospective data, and they all lack clinical validation [11, 32, 33].
In the effort of personalizing anti-angiogenic treatment an in vitro sensitivity test could be
an alternative to the aforementioned predictive biomarkers. Accordingly, tumour cells from
the individual patient could be introduced into an in vitro angiogenesis assay and evaluated for
their angiogenic potential and sensitivity to anti-angiogenic agents. Such an assay should be
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able to evaluate the combined contribution of both pro- and anti-angiogenic factors secreted
by the tumour [34, 35].
In this study we present our novel Cancer Angiogenesis Co-Culture (CACC) Assay (Fig 1).
The assay is a modification of the organotypic co-culture assay of angiogenesis developed by
Bishop et al. in which human umbilical vein endothelial cells (HUVECs) are co-cultured with
juvenile foreskin fibroblasts for 14 days, during which time the endothelial cells (ECs) formes
luminal tubules resembling capillaries in vivo [36]. The assay recapitulates the key aspects of
angiogenesis such as extension of sprouts, branching of existing structures, migration by cord
tip cells and tubulogenesis [36–38]. The assay modifications presented in this study have
allowed for co-culture of fibroblasts, vascular cells, and tumoroids established from primary
colorectal tumours or metastases and thereby enabled the study of tumour induced
angiogenesis.
Materials and methods
Culture of cell lines
Primary HUVECs were obtained from Lonza (Basel, Switzerland) and cultured in endothelial
cell growth medium-2 (EGM-2). EGM-2 medium consisted of endothelial basal medium
(EBM) supplemented with EGM-2 SigleQuot (Lonza) or SupplementPack (PromoCell,
Fig 1. Overview of the cancer angiogenesis co-culture (CACC) assay. (DAY 5) HUVECs were seeded on a confluent layer of NHDFs. (DAY 7) Following two
days of HUVEC-NHDF co-culture tumoroids/human recombinant VEGF-A165 (VEGF)/anti-angiogenic treatments were introduced to the assay in a 1:4
dilution of GFR Matrigel. (DAY 11) Samples were fixed and stained with the endothelial marker PECAM-1 to visualize tubes.
https://doi.org/10.1371/journal.pone.0253258.g001
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Heidelberg, Germany) containing 2% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO,
USA), endothelial growth factor (EGF), insulin-like growth factor (IGF), human fibroblast
growth factor 2 (bFGF), heparin, ascorbic acid, hydrocortisone, gentamicin, and amphoteri-
cin-B. EBM was either provided from Lonza, PromoCell or mixed by adding 1% fatty acid free
(FAF) bovine albumin serum (BSA; Sigma-Aldrich) to Dulbecco’s modified eagles medium
(DMEM)/F12 (Thermo Fisher Scientific, Waltham, MA, USA). Prior to HUVEC seeding, the
culture flasks were coated with 10 μg/ml fibronectin (Sigma-Aldrich) in phosphate-buffered
saline (PBS; Sigma-Aldrich) for 1h at room temperature (RT). Primary adult normal human
dermal fibroblasts (NHDFs; Batch A: Lonza, Batch B: PromoCell) and the colon cancer cell
line SW480 were cultured in DMEM (Sigma-Aldrich) with 10% FBS supplemented with 100
U/ml penicillin and 100 μg/ml streptomycin (P/S; Sigma-Aldrich). HUVEC and NHDF were
passaged every 2–3 days with split ratios 1:4–6. For experiments HUVEC cells were used in
passage 6–8 and NHDF in passage 8–10. All cell lines were cultured at 37˚C in a humidified
atmosphere with 5% CO2.
Preparation of a VEGF-expressing SW480 cancer cell line
A VEGF-expressing SW480 cell line was generated by lentiviral transduction. Human
VEGF-A165 (VEGF) was cloned into the lentiviral expression vector pLVX-Puro (Takara Bio,
Gothenburg, Sweden). The expression vector was co-transfected with pMD2.G (AddGene,
Watertown, MA, USA) and psPAX2 (AddGene) into Lenti-X™ 293T packaging cells (Takara
Bio) using PEI (Sigma Aldrich) at a final concentration of 1uM. The produced virus particles
were harvested 48 and 72hrs post transfection and filtered through a 0.4um filter. The SW480
cells were transduced with the produced viruses and a stable population of VEGF expressing
cells was isolated by selection with puromycin (2ug/ml for 48h, Thermo Fisher Scientific).
Secretion of angiogenic factors from cancer cell lines and tumoroids
The concentration of VEGF-A, bFGF and PDGF-BB was directly measured in culture super-
natants using enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer’s
recommendations. For cell line measurements R&D Systems (Minneapolis, MN, USA) and for
tumoroids Thermo Fisher Scientific (VEGF and bFGF) and R&D Systems (PDGF-BB).
Tumoroids were cultured in the CACC assay and supernatants collected on day 11. VEGF-
expressing SW480 cells (SW480-V) and the parental line were cultured to confluence and
allowed to condition the cell media for 48h. VEGF secretion was also examined qualitatively
by immunofluorescence microscopy. Briefly, cells were fixed with 4% paraformaldehyde for 15
min and permeabilized with 0.5% Triton X-100 for 5 min. Cells were incubated with VEGF
antibody (R&D systems) for 1h, followed by secondary Alexa-488 conjugated goat anti-mouse
antibody (Invitrogen Carlsbad, CA, USA) for 45 min. Accordingly, the cells were incubated
with DAPI for 5 min and mounted in Mowiol (Sigma-Aldrich) containing 2.5% 1,4-diazabicy-
clo[2.2.2]octane (DABCO) as an anti-bleaching agent. Images were obtained using a Leica
SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 inverted epi-
fluorescence microscope.
Formation of cell line spheroids
SW480 and SW480-V cells (1.5 x 105 cells) were suspended in 3 ml of complete DMEM
medium and mixed with 1.5 ml of a sterile suspension of methylcellulose (2.4% in DMEM).
The suspended cells were dispensed in drops of 30 μl onto the lids of 10 cm culture dishes
which were inverted in a humidified incubator for seven days. Subsequently, spheroids were
harvested by suspension in PBS and gentle centrifugation at 160 x g for 90s. Next, the
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spheroids were resuspended in an ice-cold mixture of 30% Geltrex (Thermo Fisher Scientific)
in complete EGM-2 medium (Lonza), for addition to the CACC assay. To visualize vessel for-
mation the cells were fixed and stained with human anti-PECAM-1 antibody (R&D systems)
in 1% BSA (Sigma-Aldrich) in PBS (1h, 37˚C), followed by Alkaline phosphatase-conjugated
secondary antibody (Novus Biologicals, Littleton, CO, USA) diluted in 1% BSA in PBS (1h,
37˚C) and treated with the substrate SigmaFAST BCIP/NBT (5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium; Sigma-Aldrich) for 15–30 min at 37˚C. Tubes were imaged
by widefield light microscopy.
Patient samples
Fresh tumour tissue was obtained from either surgically resected colonic tumours and liver
metastases before routine histological processing of the specimen or by ultrasound-guided
needle biopsies. The study protocols were approved by the Regional Committee on Health
Research Ethics—Capital Region of Denmark (protocol no. H-1-2011-125 and H-16031106)
and informed consent was obtained from all patients. Samples from primary tumours were
collected at Bispebjerg Hospital, Denmark and samples from liver metastases were collected at
Rigshospitalet, Denmark. Tumour tissue was placed in cold PBS supplemented with 2.5 μg/ml
amphotericin B (Sigma-Aldrich) and antibiotics (500 U/ml and 500 μg/ml P/S and 100 μg/ml
gentamicin (Sigma-Aldrich)) and subsequently transported to the laboratory on ice. For each
patient age, gender, and TNM stage were recorded.
Establishment of patients-derived tumoroids
Patient-derived tumoroids were established as described by Jeppesen et al. [39] with minor
modifications. In short, freshly resected tumour samples of 0.01–1 g were divided into 1
mm3 pieces and digested for 20 min at 37˚C with 1 mg/ml collagenase type II (Thermo
Fisher Scientific) diluted in STEM medium. Subsequently, the tissue suspension was
sequentially filtered through a 70 μm cell strainer (VWR, Soeborg, Denmark) and a 30 μm
pre-separation filter (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). Tissue
retained by the 70 μm filter was collected and redigested for 10 min at 37˚C and passed
through the filters again. This step was repeated until all tissue could pass through the
70 μm filter. Retained tumour fragments (30–70 μm) were seeded in STEM cell medium in
petri dishes coated with 1.5% agarose (Sigma-Aldrich) and cultured at 37˚C in a 5% CO2
humidified incubator. After 3–5 days the tissue fractions which had densified into rounded
tumoroids with smooth surfaces could be collected for further culture. Tumoroids estab-
lished from colonic tumours were denoted C after the patient number and tumoroids from
liver metastases were denoted L.
Propagation and culture of patients-derived tumoroids
To increase the size and number of tumoroids per patient, tumoroids sized 30–70 μm were
seeded in drops of 50 μl Matrigel matrix (VWR) diluted 1:2 with STEM cell medium in a
24-well dish. Following solidification (30 min, 37˚C), in a 5% CO2 humidified incubator, 1 ml
STEM cell medium was added to each well. After an average of 2 weeks, with intermediate
medium change, the tumoroids exceeding 200 μm in size could be collected for experiments
with a 200 μm pluristrainer (PluriSelect, Leipzig, Germany). Tumoroids used in this study
were thawed from the 2cureX tumoroid biobank and cultured as described above before
experiments.
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Cancer angiogenesis co-culture assay
In the original co-culture assay of angiogenesis, established by Bishop et al. [36] and later mod-
ified by Mavria and colleagues [40], endothelial cells (HUVECs) are cultured in EGM-2
medium in co-culture with fibroblasts. Under these conditions the HUVECs form tube-like
structures within the layers of fibroblasts and extra cellular matrix [36, 37, 40]. The Cancer
Angiogenesis Co-Culture (CACC) Assay established for our studies follow the same procedure
until day 7 after which the culture condition has been modified, since patient-derived tumor-
oids dissociate when cultured in EGM-2 medium. In short, NHDF were seeded in EGM-2
medium in 24-well plates at a density of 1.5–1.75x104 cells/well (batch and passage dependent
density) and allowed to grow to confluence over five days with intermediate medium change.
On day 5 the HUVEC cells were seeded onto the confluent layer of NHDF in EGM-2 medium
at a density of 1.5x104 cells/well. After two days of HUVEC-NHDF co-culture (day 7) tumor-
oids were introduced to the assay (Fig 1). The tumoroids were isolated from the culture plates
by gentle pipetting with cut-off P-1000 tips followed by filtration through a 400 μm and a
200 μm pluristrainer filter (PluriSelect). The 200–400 μm fraction of tumoroids were sus-
pended in PBS and allowed to sediment without centrifugation. Subsequently, for each well 75
tumoroids were resuspended in 250 μl ice-cold matrix solution: Growth factor reduced (GFR)
Matrigel (VWR) diluted 1:4 with reduced F12 medium (R-F12) consisting of DMEM/F12, 5%
FBS, 0.45% BSA, 0.5% FAF BSA, 0.1 mM 2-mercaptoethanol, 100 U/ml and 100 μg/ml P/S,
50 μg/ml gentamicin, and 2.5 μg/ml amphotericin B. The tumoroid solution was carefully dis-
tributed on top of the HUVEC-NHDF co-culture and incubated at 37˚C for 30 min to ensure
solidification of the matrix solution. Subsequently, 250 μl R-F12 medium ± treatment com-
pounds were gently added on top of the matrix. Medium ± treatment was changed on day 9,
and on day 11 the cells were fixed in 10% neutral buffered formalin containing 4% formalde-
hyde solution (Hounisen, Skanderborg, Denmark) for 2.5h at 4˚C with intermediate change of
formalin after 30 min. To quantify vessel formation the cells were stained with human anti-
PECAM-1 antibody (R&D systems) diluted in 1% BSA in PBS (1h, 37˚C) followed by Alexa
Fluor 488 goat anti-mouse secondary antibody (Invitrogen, 1:500 in 1% BSA in PBS) for 1h at
37˚C and counterstained with Hoechst (Sigma, 5 μM in PBS) for 5 min at RT. Treatment com-
pounds included VEGF-A165, bevacizumab, regorafenib (Selleck Chemicals, Houston, TX,
USA), sorafenib (Selleck Chemicals), and sunitinib (Selleck Chemicals). Each experiment
included positive controls obtained by treatment with 10 ng/ml VEGF-A165. Microscope
images (5x objective) of the wells were obtained with Cellomics Array Scanner VTI and a mini-
mum of 8 representative images per sample were analysed with the proprietary BioSense Solu-
tions and 2cureX tube algorithm.
Detection of cell death in the CACC assay
To investigate the induction of cell death upon treatment with anti-angiogenic compounds the
fixed culture was stained with human/mouse active caspase-3 antibody (R&D systems) together
with human anti-PECAM-1 antibody (R&D systems) diluted with 1% BSA and 1% goat serum in
PBS (1h, 37˚C), followed by the secondary antibodies Alexa Fluor 488 goat anti-mouse (1:500)
and Alexa Flour 546 Goat anti-Rabbit (Invitrogen) for 1h at 37˚C. Subsequently, the samples were
counterstained with Hoechst (5 min, RT, 5 μM in PBS). Positive controls were obtained by treat-
ment with 1 μM staurosporine (Sigma-Aldrich) for 6h prior fixation. Microscope images (10x
objective) were obtained with Cellomics Array Scanner VTI and a minimum of 10 representative
images per sample were quantified with a proprietary 2cureX algorithm. The expression of active
caspase-3 was investigated in areas covered with HUVEC cells (Active casp-3 masked Pecam-1)
and in the entire well, including areas only covered by NHDFs (total casp-3 activation).
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Statistical analysis
Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM)
and analysed by two-tailed unequal variance t-test using Excel (Microsoft, Seattle, CA, USA).
P-values less than 0.05 were considered statistically significant.
Results
VEGF treatment increased tube formation in the CACC assay
To verify that the HUVECs retained the ability to form tubes and be stimulated by pro-angio-
genic factors in the modified culture conditions, we treated with increasing concentrations of
VEGF-A. In the untreated controls HUVECs grew in short tubes with only few branches and
covered less than 10% of the investigated area (Fig 2A). VEGF-A treatment resulted in a dose-
dependent induction of tube formation. Accordingly, addition of 10 ng/ml VEGF-A induced a
two-fold increase in tube area compared to the untreated control (Fig 2B). Treatment with
VEGF-A also increased branching.
VEGF-induced tube formation was inhibited by anti-angiogenic
compounds
Treatment with known anti-angiogenic inhibitors resulted in a significant inhibition of tube
formation at concentrations from 10 ng/ml bevacizumab (p<0.05), 25 nM regorafenib
(p<0.05), 10 nM sorafenib (p<0.001), and 10 nM sunitinib (p<0.01) when compared with
VEGF-A treated samples (3.75 ng/ml VEGF-A165 without anti-angiogenic compounds) (Fig
3A–3C). 3.75 ng/ml VEGF resembled the level observed in the tumoroid cultures with the
highest amount of VEGF-secretion (patient 11-L and 12-L, Fig 5A). In addition, we found that
concentrations from 50 nM sorafenib (p<0.005) and 25 nM sunitinib (p<0.05) resulted in a
significant inhibition of tube formation when compared with vehicle treated controls (no
VEGF-A).
Tube formation concentrated around VEGF secreting spheroids
To investigate if angiogenic factors secreted from cancer cells grown in co-culture with
HUVEC cells affect tube formation we transduced the colon cancer cell line SW480 with
Human VEGF-A165 (Fig 4). Microscopic imaging of VEGF stained cell monolayers revealed
no detectable VEGF in the non-transduced cells (SW480). In contrast, the VEGF transduced
SW480 cells (SW480-V) contained VEGF-positive vesicles and a diffuse pattern of VEGF
staining beneath the cells was observed (Fig 4A). The SW480-V cells secreted almost 10 times
more VEGF than the parental SW480 as determined by ELISA (Fig 4B). Finally, in the
co-cultures we found that tube formation was directed towards the VEGF secreting spheroids
(Fig 4C).
Sphere size affects the level of accessible oxygen throughout the sphere and thereby also the
level of the vegfa transcription factor hypoxia-inducible factor α (HIF α) [41–43]. We investi-
gated the correlation between tumoroid diameter and VEGF secretion for three tumoroid cul-
tures. The results showed a 35-fold increase in average VEGF secretion between small (70-
100um) and large (200-400um) tumoroids (S1 Fig).
Patient-derived tumoroids induced tube formation
Ten different biobank cultures of large tumoroids (200–400 μm) were assessed for their ability
to induce tube formation (Table 1). We found that 7 tumoroid cultures induced a significant
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(p<0.05) increase of tube formation (Fig 5A) and these were accordingly classified as angio-
genic. Interestingly, the two cultures originating from the same patient (pt8) had similar
increases in the level of tube formation. The highest induction of tubes occurred in patient
10-L showing a 1.43-fold increase compared to the control without tumoroids (p = 0.01).
Tumoroids originating from this patient also induced a high amount of tube branching (Fig
5B) compared to the control. Tumoroids deriving from patient 5-C, 11-L and 12-L did not
result in a statistically significant increased tube formation, and such cultures were therefore
classified as non-angiogenic.
Fig 2. Dose-response curve following treatment with the pro-angiogenic VEGF-A165 (VEGF). HUVECs were seeded
on a confluent layer of NHDF on day 5 and cultured with increasing concentrations of VEGF (0–15 ng/ml) from day 7.
At the end of the experiment (day 11), the co-cultures were fixed and stained for the endothelial marker PECAM-1 to
reveal the tubes. (a-g) Representative fluorescent images (5x) obtained with the Array Scanner VTI with green overlay
from the tube algorithm of PECAM-1 positive cells following treatment with (a) 0 ng/ml VEGF (Control), (b) 2.5 ng/ml
VEGF, (c) 3.75 ng/ml VEGF, (d) 5 ng/m VEGF, (e) 7.5 ng/ml VEGF, (f) 10 ng/ml VEGF or (g) 15 ng/ml VEGF. Bar
200 μm. (h) Quantification of tube area in samples treated with increasing concentrations of VEGF. Tubes were
quantified with the BioSense Solutions and 2cureX tube algorithm. Two independent experiments were performed with
representative results displayed. Data are the average of triplicate samples ± SD.
https://doi.org/10.1371/journal.pone.0253258.g002
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Fig 3. Dose-response curves following treatment with anti-angiogenic compounds. HUVECs were seeded on a confluent layer of
NHDFs on day 5 and cultured with 3.75 ng/ml VEGF-A165 (VEGF) and increasing concentrations of the anti-angiogenic compound
from day 7. At the end of the experiment (day 11), the co-cultures were fixed and stained for the endothelial marker PECAM-1 to reveal
the tubes. Tube formation is expressed relative to a vehicle treated control. Quantification of tube area in samples treated with increasing
concentrations of (a) bevacizumab, (b) regorafenib, (c) sorafenib, and (d) sunitinib. Tubes were quantified with the BioSense Solutions
and 2cureX tube algorithm. Two individual experiments were performed for each treatment with representative results displayed. Data
PLOS ONE The angiogenic potential of tumoroids
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Increased tube formation did not correlate with secreted levels of
antiangiogenic factors
All tumoroids secreted a measurable amount of VEGF-A (Fig 5A). The concentrations ranged
from 0.99 ng/ml (patient 9-L) to 3.89 ng/ml (patient 12-L) with a median value of 1.76 ng/ml.
The base level of VEGF-A secreted from NHDF, HUVEC cells, and medium was less than 0.1
ng/ml in all investigated control samples. Interestingly, there was no correlation between a
high level of secreted VEGF-A and induction of tube formation.
The amount of tumoroid-secreted bFGF and PDGF-BB in the angiogenic tumoroid cul-
tures were also investigated by ELISA (S2 Fig). The bFGF concentrations ranged between 59
and 90 pg/ml, with an average of 69 pg/ml. The PDGF-BB concentrations ranged between 189
pg/ml and 302 pg/ml, with an average of 224 pg/ml. These concentrations were similar to the
control samples 80pg/ml and 203pg/ml for bFGF and PDGF-BB respectively (S2 Fig).
are the average of triplicate samples ± SD. � p<0.05 for treated samples vs. control. # p<0.05 for anti-angiogenic treated vs. VEGF
treated samples.
https://doi.org/10.1371/journal.pone.0253258.g003
Fig 4. Vessel growth is directed towards the colon cancer spheroids secreting VEGF- A (VEGF). (a) SW480 and a SW480
cell line expressing VEGF (SW480-V) were fixed and stained for VEGF (green) and nuclei (DAPI; blue) and imaged by
confocal microscopy. Bar 10μm. (b) SW480 and SW480-V cells were grown to confluence and allowed to condition fresh cell
culture medium for 48h. The medium was removed and assayed for VEGF by ELISA. Data are the average of three
independent experiments ± SEM. (c) Spheroids of SW480 and SW480-V cells were introduced into the co-culture assay of
angiogenesis. Vessels were detected by staining for PECAM-1 and imaged by widefield light microscopy. Spheroids (arrows).
Bar 250 μm.
https://doi.org/10.1371/journal.pone.0253258.g004
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Fig 5. Patient-derived tumoroids can induce increased tube formation. Tumoroids were introduced to the CACC assay on day 7. At
the end of the experiment (day 11) the co-cultures were fixed and stained for the endothelial marker PECAM-1 to reveal the tubes.
Tubes were quantified with the BioSense Solutions and 2cureX tube algorithm. (a) Left axis: Relative tube formation (RTF) for 10
patient-derived tumoroid cultures. Tube formation is expressed relative to control sample without tumoroids. Data are the average of
triplicate samples ± SD, � p<0.05 for samples with tumoroids vs. control. Right axis: Tumoroid-secreted VEGF-A (VEGF) measured in
culture medium collected from the CACC assay (day 11) and assayed for VEGF by ELISA. Data are the average of triplicate
samples ± SD. (b) Representative images (5x objective) of tube formation on day 11 following addition of tumoroids from patient 1x0-L
(high induction of tubes), patient 6-C (high to medium induction of tubes) and patient 12-L (no induction of tubes). Images were
obtained with the Array Scanner VTI and are shown with green (tubes) and red (tumoroids) overlay from the analysis algorithm. Left
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Tumoroid-induced tube formation could be inhibited by bevacizumab
After addition of 1 μg/ml bevacizumab, we found that the tumoroid-induced tube formation
in 8 of the 10 cultures was significantly reduced compared with samples containing only
tumoroids (p<0.05) (Fig 5B and 5C). In two of the cultures (4-C and 7-C) 1 μg/ml bevacizu-
mab reduced the tube formation to a level significantly lower than the control (no tumoroids,
no treatment, p<0.05), and addition of 3 μg/ml bevacizumab resulted in tube formation below
the level of the control for 7 out of 10 patients (p<0.05). For patient 11-L and 12-L a significant
reduction in tube formation was not observed after addition of bevacizumab.
Tumoroid-induced tube formation could be inhibited by regorafenib,
sorafenib, and sunitinib
Three of the patient-derived tumoroid cultures were chosen to investigate if other anti-angio-
genic compounds than bevacizumab could reduce tumoroid-induced tube formation (Fig 6).
All of the investigated TKIs induced a significant reduction in tube formation at concentra-
tions of 50 nM and above (p<0.05) when compared with the untreated tumoroid control sam-
ples. The most potent inhibitor was sorafenib, which induced a significant reduction in tube
formation even at 10 nM (p<0.05). Addition of sorafenib also resulted in tube formation
below the level of untreated controls (without tumoroids) at a concentration of 25 nM for cul-
ture 6-C (p<0.01) and 10-L (p<0.005). This was observed in all cultures for sunitinib and
regorafenib at 50 nM and 100 nM, respectively (p<0.05).
In addition to the ten tumoroid cultures from the 2cureX tumoroid biobank, we also estab-
lished two new tumoroid cultures from liver metastases biopsies (13-L and 14-L) and investi-
gated the effect of adding these cultures to the CACC assay. On average, 13-L induced a
1.55-fold increase in tube formation compared with the control without tumoroids (p<0.005),
column: Tumoroids in control medium. Right column: Tumoroids treated with 1μg/ml bevacizumab (Bev) from day 7 of the CACC
assay. Bar 200 μm. (c) Relative tube formation upon addition of patient-derived tumoroids and treatment with 1 or 3 μg/ml bevacizumab
from day 7 to 11 in the CACC assay. Tube formation is expressed relative to samples with tumoroids (no treatment). Pt: Patient � p<0.05
for samples vs. control (no tumoroids, no treatment). # p<0.05 for samples vs. tumoroids (no treatment). Data are the average of
triplicate samples ± SD.
https://doi.org/10.1371/journal.pone.0253258.g005
Table 1. Overview of patients selected for investigations with the cancer angiogenesis co-culture assay.
Patient Sample Gender Age (Year) T N M Histologic subtype
4-C Colon F 83 T2 N0 M0 Glandular
5-C Colon M 76 T3 N2 M0 Glandular
6-C Colon M 76 T3 N1 M1 Glandular
7-C Colon M 83 T3 N0 M0 Glandular
8-C Colon Biopsy F 45 T4 N2 M1 Mucinous
8-L Liver Biopsy F 45 - - - N/A
9-L Liver F 51 - - - Glandular
10-L Liver F 75 - - - Low Differentiated
11-L Liver M 77 - - - Glandular
12-L Liver M 59 - - - Glandular
13-L Liver Biopsy N/A N/A - - - N/A
14-L Liver Biopsy N/A N/A - - - N/A
Colonic tumors were classified according to the tumour (T), node (N), and metastasis (M) system. C: Colon, N/A: Not available. F: Female, L: Liver, M: Male.
https://doi.org/10.1371/journal.pone.0253258.t001
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while 14-L induced a 1.79-fold increase in tube formation (p<0.05) (Fig 7). The amount of
tube formation was investigated after addition of increasing concentrations of bevacizumab
(0.01, 0.1, and 1 μg/ml), regorafenib (10, 50, and 100 nM) and sorafenib (10, 25 and 50 nM).
Interestingly, 13-L tumoroid-induced tube formation was inhibited by less than 20% when
treated with 1 μg/ml bevacizumab while tube formation was reduced by 54% in patient 14-L at
the same drug concentration.
Fig 6. Anti-angiogenic compounds can abolish tumoroid-induced tube formation. Tumoroids were introduced to the
CACC assay on day 7 ± treatment compounds. At the end of the experiment (day 11) the co-cultures were fixed and
stained for the endothelial marker PECAM-1 to reveal tubes. The cultures were treated with increasing concentrations of
regorafenib (Reg; 10, 50 and 100 nM), sorafenib (Sor; 10, 25 and 50 nM), and sunitinib (Sun; 10, 25 and 50 nM). (a) Tube
formation was quantified with the BioSense Solutions and 2cureX tube algorithm and expressed relative to sample with
tumoroids (no treatment). Data are the average of triplicate samples ± SD, � p<0.05 for samples vs. control (no
tumoroids, no treatment). # p<0.05 for samples vs. tumoroids (no treatment). (b) Representative images (5x objective) of
tube formation on day 11 following addition of tumoroids from patient 6-C, 7-C and 10-L. Images were obtained with the
Array Scanner VTI and are shown with green (tubes) and red (tumoroids) overlay from the analysis algorithm. Bar
200 μm.
https://doi.org/10.1371/journal.pone.0253258.g006
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Inhibition of tube formation was not driven by endothelial cell death
None of the angiogenic inhibitors induced a significant increase in HUVEC or NHDF cell
death (active casp-3) at the investigated concentrations (Fig 8). Concurrently, the positive con-
trol which was treated with the known cell death inducer staurosporine induced at more than
two-fold induction of cell death in both NHDFs and HUVEC covered areas.
Fig 7. Tumoroids established from liver metastases express different sensitivities to anti-angiogenic treatments. Tumoroids were introduced to the CACC assay
on day 7 ± treatment compounds. At the end of the experiment (day 11) the co-cultures were fixed and stained for the endothelial marker PECAM-1 to reveal tubes.
The cultures were treated with increasing concentrations of bevacizumab (Bev; 0.01, 0.1 and 1 μg/ml), regorafenib (Reg; 10, 50 and 100 nM), and sorafenib (Sor; 10, 25,
and 50 nM). (a) Tube formation was quantified with the BioSense Solutions and 2cureX tube algorithm and expressed relative to sample with tumoroids (no
treatment). Data are the average of triplicate samples ± SD, � p<0.05 for samples vs. control (no tumoroids, no treatment). # p<0.05 for samples vs. tumoroids (no
treatment). (b) Representative images (5x objective) of tube formation obtained with the Array Scanner VTI shown with green (tubes) and red (tumoroids) overlay. Bar
200 μm.
https://doi.org/10.1371/journal.pone.0253258.g007
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Discussion
In the present paper we determined the angiogenic potential and anti-angiogenic treatment
sensitivity of 12 tumoroid cultures established from primary colorectal tumours or liver metas-
tasis, thus opening the door for personalized therapy. They were all evaluated for their sensitiv-
ity towards bevacizumab and five of the cultures were also evaluated for their sensitivity
towards three different TKIs.
Patient-derived tumoroids and organoids are important 3D model systems since they pres-
ent individual drug response profiles and can predict the response to chemotherapy with high
sensitivity and specificity [39, 44–47]. Such microtumour cultures can be propagated in vitro
and frozen in biobanks [44, 45, 48]. The main target of most anti-angiogenic agents is the
tumour vasculature and accordingly the ECs. These cells have not been incorporated into pre-
vious tumoroid and organoid chemosensitivity assays, and prediction of sensitivity to anti-
angiogenic agents was therefore not feasible.
Fig 8. Anti-angiogenic compounds can abolish tube formation without induction of cell death. HUVECs were seeded on a confluent layer of NHDFs
on day 5 and cultured with 3.75 ng/ml VEGF-A165 (VEGF) from day 7 ± increasing concentrations of the anti-angiogenic compounds bevacizumab (0.01,
1 and 10 μg/ml), regorafenib (10, 50 and 100 nM), sorafenib (10, 25 and 50 nM), and sunitinib (10, 25 and 50 nM). At the end of the experiment (day 11),
the co-cultures were fixed and stained for the endothelial marker PECAM-1 and the apoptotic marker active caspase-3 (Casp-3) to reveal tubes and
apoptotic cells, respectively. Left axis: Relative tube formation. Tube formation is expressed relative to the untreated control. Right axis: Relative active
caps-3. Active casp-3 is expressed relative to the VEGF treated sample. Active casp-3 masked PECAM-1: Active casp-3 in areas covered with HUVEC cells.
The positive control was treated with 1 μM staurosporine for 6h prior fixation. Tubes were quantified with the 2cureX tube and casp-3 algorithm. Two
individual experiments were performed, and representative results are shown. Data are the average of triplicate samples ± SD. �, †, # p<0.05 for anti-
angiogenic treated vs. VEGF treated samples with respect to tube formation, total casp-3 activation in the sample and active casp-3 masked PECAM-1,
respectively.
https://doi.org/10.1371/journal.pone.0253258.g008
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Many 3D in vitro methods for studying tumour angiogenesis use embedding of cancer
cells, cancer cell line spheroids or freshly resected cancer tissue into a matrix gel with or with-
out addition of ECs or stromal cells such as fibroblasts and pericytes [34, 35, 49, 50]. Such
assays are adequate models of in vivo angiogenesis, but their ability to deliver rapid and quanti-
fiable readouts are inferior since the resulting tube formation and infiltration are scattered
throughout the matrix. Our CACC assay is a novel 3D in vitro model of tumour angiogenesis
employing patient-derived tumoroids co-cultured with tube forming HUVECs and fibroblasts.
The confluent layer of fibroblasts is only 3–5 cells in thickness and thereby enables microscopy
in a single plane while concurrently allowing the ECs and tumoroids to be cultured in a micro-
environment that includes stromal cells and extra cellular matrix (ECM) [38].
The Z’ factor is a measure of the quality of a screening assay and ranges from -1 to 1. An
ideal assay would have a Z’-factor of 1, and a screening assay is generally classified as excellent
if 1> Z’� 0.5 [51, 52]. Z’ incorporates the dynamic range (the difference between the means
of the negative and positive control) and the separation band (the difference between the SD of
the negative and positive control). Based on the data from Fig 2, we calculated a Z’ factor of
0.54 for the CACC assay meaning that the assay qualifies as an excellent screening assay. An
important aspect when developing a screening assay to be utilized in a clinical setting is repro-
ducibility, speed, and cost-effectiveness. The CACC assay was developed using HUVECs as
these ECs are widely available and reported to represent a robust source of primary human
ECs in the organotypic co-culture assay of angiogenesis [53, 54]. This is supported by the fact
that different batches of HUVEC cells demonstrated the same angiogenic potential upon treat-
ment with pro-angiogenic factors. The assay also proved highly reproducible when the same
tumoroid cultures were investigated in repeated independent experiments (S3 Fig).
Another important aspect during assay development was to verify that the observed inhibi-
tion of tube formation was not mediated by inducing cell death in the ECs. We therefore inves-
tigated whether treatment with bevacizumab, regorafenib, sorafenib or sunitinib led to
increased apoptosis in both fibroblasts and more importantly the ECs of the CACC assay. The
results (Fig 8) show that none of the anti-angiogenic treatments resulted in significant increase
in apoptosis in neither the fibroblast nor the ECs at the investigated concentrations. This sup-
ports that the treatments reduced tube formation through their anti-angiogenic properties and
not by inducing apoptosis in the ECs.
The majority of our results were obtained using biobanked tumoroid cultures. To investi-
gate whether the CACC assay results were affected by the biobanking procedure, we per-
formed the CACC assay on two fresh tumoroid cultures (pt13-L and pt14-L) (Fig 7). The
results show that the tube formation with fresh tumoroids was morphologically indistinguish-
able from the biobanked tumoroid cultures. The two fresh cultures had the highest observed
RTF but whether this was due to the age of the tumoroid cultures is unknown. These results
emphasize the value of using biobanked tumoroid cultures for assay development. Nine
tumoroid cultures were classified as angiogenic and three as non-angiogenic. Tumoroid cul-
tures presented with individual angiogenic profiles since the induced relative tube formation
values ranged from 0.93 to 1.79 (Figs 5A and 7). Interestingly we observed that tumoroids
deriving from the primary and metastatic lesions from the same patient (pt8) exhibited a simi-
lar angiogenic potential. It is rare to obtain samples from both primary and metastatic lesions;
however, it would be interesting to investigate the angiogenic potential in more of these dual
lesion patients.
The CACC assay only depicts angiogenesis but some tumours use e.g. vessel co-option to
supply vessels. Bevacizumab was designed to inhibit sprouting angiogenesis and not tumour
co-option of mature peritumoral vessels [31]. In mCRC up to 30% of liver metastases predomi-
nantly present with the histopathological growth pattern (HGP) termed replacement-HGP.
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This pattern is characterized by co-opting of the peritumoral vessels and may explain why
treatment with bevacizumab does not prolong the OS of some patients [31, 55, 56]. A retro-
spective explorative study investigating the predictive value of HGP showed that the OS was
significantly shorter for the cohort of bevacizumab treated patients with replacement-HGP
[31]. However, HGP patterns can only be determined on resected liver tumours [56], and is
therefore not a suitable biomarker for the choice of anti-angiogenic agents in patients with
non-resectable tumours. Possibly, the non-angiogenic tumoroid cultures (patient 5-C, 11-L
and 12-L) derive from co-opting tumours and these patients may not benefit from bevacizu-
mab treatment.
The tube formation detected in the CACC assay represents the cumulative effect of both
pro- and anti-angiogenic factors in the sample. We observed no correlation between the
amount of tumoroid-secreted VEGF-A and induction of tubes (Fig 5A) confirming that
VEGF-A is not the only angiogenic factor regulating the process of angiogenesis. These find-
ings are consistent with several clinical studies showing that VEGF-A levels did not correlate
with the functional effect of bevacizumab treatment [27, 57–59]. The ELISA assay measured
the combined amount of the VEGF-A isoforms and differences between isoform levels within
each tumoroid culture are therefore unknown. It would be interesting to investigate how iso-
form patterns differ between patients and whether this has an impact on the tube induction.
Since the non-angiogenic tumoroids (patient 5-C, 11-L, and 12-L) secreted VEGF-A, the
tube formation in these samples are probably inhibited by endogenous anti-angiogenic factors.
The tumoroids from patient 13-L induced the second highest tube formation among the 12
investigated tumoroid cultures. However, the 13-L culture was largely non-sensitive to bevaci-
zumab (Fig 7) suggesting that VEGF-A was probably not a major angiogenic driver for this
tumour. Likewise, it is unlikely that the lack of response to bevacizumab was caused by tumour
co-option but rather the interplay of several pro-angiogenic factors since the TKIs regorafenib
and sorafenib could obliterate tube formation in this culture.
To investigate the potential effect of other angiogenic factors the amount of tumoroid-
secreted bFGF and PDGF-BB were also evaluated by ELISA (S2 Fig). The measured concentra-
tions of both bFGF and PDGF-BB for angiogenic cultures were all similar to that of the con-
trols. These results indicate that neither bFGF nor PDGF-BB are likely to have significantly
contributed to the higher tube formation observed in the angiogenic cultures. For bFGF this
correlates well with published results in a similar tube formation assays where co-cultures of
HUVEC and NHDF were treated with increasing concentrations of bFGF. The EC50 value of
bFGF was found to be 1400 pg/ml [60], which is more than 14 times higher than the highest
bFGF concentration found in our angiogenic cultures. We only measured the soluble forms of
VEGF-A, bFGF and PDGF-BB and it is unknown whether ECM bound forms are sequestered
within the matrix and how they would influence tube formation.
We tested three different TKIs (regorafenib, sorafenib, sunitinib) for their ability to inhibit
tube formation. For all investigated tumoroid cultures we saw a dose dependent inhibition of
tube formation for each of the TKIs (Figs 6 and 7). The three TKIs tested are multi-kinase
inhibitors targeting several of the kinases associated with angiogenesis [22–24]. As discussed
above tumoroids from patient 13-L were largely insensitive to bevacizumab but showed sensi-
tivities towards regorafenib and sorafenib which were equal to that of the other investigated
tumoroid cultures (Fig 7). This once again emphasises that angiogenesis is regulated by multi-
ple pro-angiogenic factors and suggest that treatment with more broad-spectrum kinase inhib-
itors in some cases could improve the overall treatment response compared to treatment with
more targeted drugs such as the monoclonal antibody bevacizumab.
The present study shows that angiogenesis, as measured in our CACC assay, is a complex
interplay between multiple inducers and inhibitors of tube formation and that the assay can
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stratify tumoroid cultures as sensitive or resistant to anti-angiogenic therapy thus potentially
profile the individual patients´ expected drug responses in vitro. The secretion data emphasises
that measurements of single drug targets for either monoclonal antibodies or TKIs (e.g. VEGF,
bFGF or PDGF-BB) cannot account for the cumulative effect of all present pro- and antiangio-
genic factors.
The patients included in this study were all curatively resected, consequently, it was not
possible to correlate our results with patient outcome as the patients were not offered anti-
angiogenic treatments. Validation of the ability of the test to predict resistance or sensitivity
towards a specific anti-angiogenic treatment in the individual patient requires prospective
clinical trials comparing the assay results with patient outcome and such trials will hopefully
be conducted in the near future.
Supporting information
S1 Fig. VEGF secretion from small and large tumoroids. Tumoroids sized 70–100 μm
(n = 40) and 200–400 μm (n = 10) were seeded in a 96-well plate and conditioned media were
collected following 7 days of culture to measure the level of tumoroid-secreted VEGF by
ELISA. Data are the average of triplicate samples ± SD.
(TIF)
S2 Fig. Tumoroid-secreted angiogenic factors. (a) Tumoroid-secreted bFGF measured in
culture medium collected from the CACC assay and assayed for bFGF by ELISA. Data are the
average of triplicate samples ± SD. (b) Tumoroid-secreted PDGF BB measured in culture
medium collected from the CACC assay and assayed for PDGF BB by ELISA. Data are the
average of duplicate samples ± SD.
(TIF)
S3 Fig. The relative tube formation of a tumoroid culture is stable between independent
experiments. Tumoroids were introduced to the CACC assay on day 7. At the end of the
experiment (day 11) the co-cultures were fixed and stained for the endothelial marker
PECAM-1 to reveal the tubes. Tubes were quantified with the BioSense Solutions and 2cureX
tube algorithm. Tube formation is expressed relative to control sample without
tumoroids ± SD. Data are the average of 4 independent experiments for Pt 6-C, Pt 7-C and Pt
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